Navigation Links
Unilens Vision Reports Increased Royalty Income

21st Consecutive Profitable Quarter Earns $.08 Per Diluted Share

LARGO, Fla., May 28 /PRNewswire-FirstCall/ -- Unilens Vision Inc. (OTC Bulletin Board: UVICF) (TSX Venture Exchange: UVI), which develops, licenses, manufactures, distributes and markets specialty contact lenses, today reported its operating results for the third quarter and first nine months of FY2008.

Net sales, excluding royalty income, for the quarter ended March 31, 2008 increased to $1,668,397 compared with $1,634,429 in the prior-year quarter ending March 31, 2007 an increase of 2.1%. The increase was primarily the result of continued growth of the Company's C-Vue multifocal contact lenses, which increased approximately 11% in the current quarter, which was partially offset by sales of our replacement products lines that declined as expected.

Royalty income for the quarter increased 15.3% to $628,993 compared with $545,293 in the prior-year quarter. Sales of licensed products by our licensee Bausch & Lomb continue to increase, resulting in continued double digit royalty income growth.

For the quarter, the Company reported net income of $368,730, or $0.08 per diluted share, compared with net income of $372,355 or $0.08 per diluted share in the prior-year quarter.

For the nine months ended March 31, 2008, net sales excluding royalty income, increased 3.8% to $4,854,119 as compared to $4,677,358 for the prior- year period. Net sales of the Company's C-Vue multifocal contact lenses increased approximately 12% during the first nine months of fiscal year 2008, while sales of replacement products lines declined, as expected.

Net Income for the nine months increased 24.2% to $1,121,941, or $0.25 per diluted share, compared with $903,697, or $0.20 per diluted share in the prior-year period.

Royalty income for the nine months ended March 31, 2008 increased 21.1% to a record $1,888,641, compared with $1,559,496 in the prior-year period, demonstrating continued increased demand for sales of licensed products by our licensee Bausch & Lomb.

"We are pleased to report our 21st consecutive quarter of profitability driven by increased royalty income from Bausch and Lomb's multifocal sales utilizing our patented licensed technology," stated Michael J. Pecora, Chief Executive Officer of Unilens Vision Inc. "Sales of our C-Vue brand disposable multifocal and single vision lenses also continue to steadily increase, achieving double digit growth."

"Earlier this month, we added to our C-Vue brand with the launch of the C- Vue 1DAY daily disposable single vision lens. This new offering expands the Company's portfolio of soft lens products, serving the rapidly growing one- time use daily disposable single vision market," concluded Mr. Pecora. The Company will market the lens under the C-Vue brand exclusively to licensed eye care professionals.

About Unilens Vision Inc. - "The Eye Care Professionals Specialty Contact Lens Company"

Established in 1989, Unilens Vision Inc., through its wholly owned subsidiary Unilens Corp., USA, located in Largo, Florida, develops, licenses, manufactures, distributes and markets specialty contact lenses under the C- Vue, Unilens, Sof-Form, Aquaflex, SoftCon, Lombart, and LifeStyle brands. Additional information on the Company may be accessed on the Internet at . The Company's common stock is listed on the OTC Bulletin Board under the symbol "UVICF" as well as the Canadian TSX Venture Exchange under the symbol "UVI."

(Note: All financial information in this release is stated in U.S. Dollars.)

The information contained in this news release, other than historical information, consists of forward-looking statements that involve risk and uncertainties that could cause actual results to differ materially from those described in such statements. For a discussion of certain factors that could cause actual results to differ materially from those described in the forward- looking statements, please refer to the Company's most recent filings with the SEC and the TSX Venture Exchange. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

For more information, please contact:

Leonard F. Barker, CFO, Unilens Vision Inc. at (727) 544-2531




(All figures in U.S. Dollars)


Three Three

Months Months Nine Months Nine Months

Ended Ended Ended Ended

March 31, March 31, March 31, March 31,

2008 2007 2008 2007

Sales $ 1,668,397 $ 1,634,429 $ 4,854,119 $4,677,358

Cost of sales 964,952 855,443 2,754,802 2,569,902

703,445 778,986 2,099,317 2,107,456

Expenses 706,041 698,067 2,176,183 2,186,419

(Loss) income from

operations (2,596) 80,919 (76,866) (78,963)

Other items:

Royalty income 628,993 545,293 1,888,641 1,559,496

Other (expense) income 1,845 (703) (47,071) (390)


income (loss) (1,044) 212 1,968 (1,717)

Interest income 3,995 9,476 23,279 30,845

633,789 554,278 1,866,817 1,588,234

Income before tax 631,193 635,197 1,789,951 1,509,271

Income tax expense 262,463 262,842 668,010 605,574

Net income for the

period $ 368,730 $ 372,355 $ 1,121,941 $ 903,697

Net income per common


Basic $ 0.08 $ 0.08 $ 0.25 $ 0.20

Diluted $ 0.08 $ 0.08 $ 0.25 $ 0.20


Provided (used) by:


activities $ 893,412 $ 739,395 $ 1,848,658 $1,517,749


activities (33,699) (51,187) (63,458) (141,141)

Financing activities (409,564) (326,491) (2,563,136) (1,774,879)

(Decrease) increase

in cash $ 450,149 $ 361,717 $ (777,936) $ (398,271)


June 30, March 31, March 31,

2007 2008 2007

Cash $ 1,961,712 $ 1,185,744 $ 1,795,645

Total assets 7,987,808 6,489,924 7,956,755

Current liabilities 819,005 762,316 855,725

Total liabilities 819,005 762,316 855,725

Stockholders' equity $ 7,168,803 $ 5,727,608 $ 7,101,030

SOURCE Unilens Vision Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Unilens Launches Aspheric C-VUE(R) Daily Disposable Lens
2. Unilens Vision Inc. Declares Regular Quarterly Cash Dividend of U.S. $0.09 Per Share
3. Unilens Vision Reports 70% Increase in Second Quarter Earnings on Higher Sales and Record Royalty Income
4. Unilens Vision Inc. Declares Regular Quarterly Cash Dividend of U.S. $0.09 Per Share
5. Unilens Vision Reports Record First Quarter Earnings and Royalty Income
6. Unilens Names Eschenbach Optik Exclusive Worldwide Distributor of the UniVision(R) Low Vision Lens
7. IMTEC Introduces New Vision Software
8. Delray Beach Soccer Club Signs Division One College Soccer Coaches
9. Lutein and Zeaxanthin Improve Sports Vision for Athletes
10. World Vision Appealing for $2 Million for Deadly China Quake
11. AVMA Declares Preliminary Victory on Farm Bill Provisions
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in the traditional ... models of traditional and far-infrared saunas. , For traditional saunas, Finnleo is ... traditional Finnish sauna wood, and Finnleo uses only European Grade A Nordic White Spruce ...
(Date:11/25/2015)... ... 26, 2015 , ... Ministers, senior government and UN agencies, ... Centres of Excellence, and public R&D institutions, civil societies and other partners gathered ... 5th African Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The three- ...
(Date:11/25/2015)... ... November 25, 2015 , ... Lakeview Health, a Jacksonville-based drug ... their sobriety and show through pictures what a positive difference it makes. The ... with the hashtag #FacesOfGratitude on their Facebook, Twitter, and Instagram accounts. Short ...
(Date:11/25/2015)... ... November 25, 2015 , ... The McHenry County law firm of ... decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys Botto and ... Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, Adcock testified that ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Beddit® has ... Beddit Classic sleep tracking systems. The new app features a more intuitive SleepScore™ that ... understand how well you slept. The SleepScore is created by a proprietary algorithm. Beddit ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 25, 2015 Allergan plc (NYSE: ... Rugen Therapeutics, a start-up  biotechnology company focused on ... disorders and funded by the F-Prime Biomedical Research ... into an exclusive collaboration to support the discovery ... Disorders (ASD) and Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... 2015 USP 800 applies to all ... pharmacists, pharmacy technicians, nurses, physicians, physician assistants, home ... also covers all entities which store, prepare, transport, ... healthcare institutions, patient treatment clinics, physicians, practice facilities, ... --> What is the purpose of ...
(Date:11/25/2015)... 2015 Asia -based ... BioLight and the New Investors will make a direct ... a private placement. The financing will help IOPtima to ... used in the treatment of glaucoma, as well as ... IOPtimate™ system with the U.S. Food and Drug Administration, ...
Breaking Medicine Technology: